From R&D to Market: Why the Product Lifecycle…

Why the Product Lifecycle Should Guide Development Strategy

Developing a medical device rarely follows a straight line. The journey from early research to market launch can take several years, and the product that eventually enters the market often differs significantly from the original concept.

During the webinar "From R&D to market: IP and regulatory strategy across the product life cycle", Anne-Sophie Grell emphasised that companies should view the product lifecycle as a strategic framework rather than simply a development timeline.

When regulatory strategy, intellectual property protection, and product development evolve together, they provide a structured path from concept to market entry and beyond.

The Risk of Sequential Thinking

Many organisations still approach innovation in a sequential way.

First comes product innovation. Then intellectual property protection. Then regulatory approval.

At first glance, this sequence seems logical. In practice, however, it creates significant risk.

Decisions made during early development influence every stage that follows. If regulatory requirements are considered too late, companies may need to redesign the product, adjust their development strategy, or generate additional evidence to meet regulatory expectations.

These corrective actions often lead to delays, increased costs, and lost competitive advantage.

What Early Planning Really Means

Effective lifecycle planning starts with a clear product definition.

Before development progresses too far, companies should address key questions such as:

What is the intended use of the product?
Which patient population will it serve?
Which markets will be targeted?
How will the product be classified under the applicable regulatory framework?

These early decisions shape the entire regulatory pathway. They determine which standards apply, what type of clinical evidence is required, and how the development process must be structured.

For MedTech companies operating under the EU Medical Device Regulation (MDR), these decisions also influence the involvement of a Notified Body and the complexity of the conformity assessment process.

The Regulatory Roadmap as a Living Document

Anne-Sophie described the regulatory roadmap as a living document that evolves throughout development.

Rather than a static checklist, the roadmap should be updated continuously as the product and development strategy mature.

A comprehensive regulatory roadmap typically includes:

regulatory classification and conformity assessment pathway
applicable standards and regulatory requirements
clinical development strategy
Notified Body engagement planning
post-market obligations and surveillance planning

Planning these elements early allows companies to anticipate regulatory timelines, resource requirements, and potential development challenges.

In practice, the regulatory roadmap becomes the strategic guide that connects development activities with regulatory expectations.

CE Marking Is Not the End of the Journey

A common misconception among early-stage MedTech companies is that regulatory work ends once CE marking is obtained.

In reality, CE marking marks the beginning of the product's market lifecycle.

Under MDR, manufacturers must maintain continuous regulatory oversight after market entry. Key obligations include:

Post-Market Surveillance (PMS)
Post-Market Clinical Follow-Up (PMCF)
vigilance reporting and incident management
device traceability and UDI registration
ongoing regulatory documentation updates

These responsibilities require planning and resources that extend well beyond the initial approval stage.

Companies that anticipate these requirements early are better prepared to maintain regulatory compliance throughout the product lifecycle.

The Bigger Picture: Lifecycle Thinking Drives Successful Innovation

Successful MedTech companies rarely treat product development as a series of isolated steps.

Instead, they treat innovation as a lifecycle strategy where regulatory planning, product development, and intellectual property protection evolve together.

This integrated approach allows companies to:

reduce regulatory uncertainty
anticipate evidence requirements earlier
align development with regulatory pathways
protect innovation more effectively
accelerate market access

In other words, regulatory strategy should not begin shortly before market approval. It should guide how the product is designed, developed, documented, and maintained from the very beginning.

What You'll Learn in the Webinar

In the webinar "From R&D to market: IP and regulatory strategy across the product life cycle", Anne-Sophie Grell and Stijn Lagaert explore how companies can align innovation strategy with regulatory and IP considerations.

Topics covered include:

how to define your product and regulatory pathway before development begins
the key regulatory milestones across the full product lifecycle for both medicinal products and medical devices
what an IP strategy integrated with your regulatory pathway looks like in practice
the latest developments in MDR, including the December 2025 amendment proposal and its implications for software manufacturers and SMEs
post-market considerations, including regulatory obligations and IP protection strategies
practical insights and real-world examples from both experts' experience

Watch the Full Webinar on Demand

This article is based on the webinar:

"From R&D to market: IP and regulatory strategy across the product life cycle" by QbD Group, Gevers & Biovia

In this session, experts explore how regulatory strategy, intellectual property, and product development interact throughout the lifecycle of innovative healthcare technologies.

Speakers: Anne-Sophie Grell (Regulatory Affairs Manager, QbD Group) and Stijn Lagaert (Patent Attorney, Gevers). Webinar held on 26 February 2026, available on demand.

About the Author

Anne-Sophie Grell

PhD Physics, MSc Medical Physics · Manager Regulatory Affairs – Medical Devices

Anne-Sophie is a Regulatory Affairs leader with over two decades of experience in medical physics, diagnostic imaging, and medical device regulation. She supports clients navigating EU MDR, FDA, and international regulatory frameworks.

View all articles